Is it time to definitely abandon neuroprotection in acute ischemic stroke?

Stroke

Volumn 39, Issue 6, 2008, Pages 1659-1660

  Sacchetti, Maria Luisa ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute care; Neuroprotection; Thrombolysis

Indexed keywords

ALTEPLASE; DISUFENTON SODIUM; NEUROPROTECTIVE AGENT; FIBRINOLYTIC AGENT;

BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; HUMAN; NEUROPROTECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REPERFUSION INJURY; TREATMENT OUTCOME; ACUTE DISEASE; BRAIN; BRAIN ISCHEMIA; CELL PROTECTION; DRUG COMBINATION; EMERGENCY HEALTH SERVICE; METABOLISM; NOTE; PATHOPHYSIOLOGY; STANDARD; STATISTICS; STROKE;

ACUTE DISEASE; BRAIN; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; CYTOPROTECTION; DRUG COMBINATIONS; EMERGENCY MEDICAL SERVICES; FIBRINOLYTIC AGENTS; HUMANS; NEUROPROTECTIVE AGENTS; REPERFUSION INJURY; STROKE; TREATMENT OUTCOME;

EID: 46249110404     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.505024     Document Type: Editorial

References (24)

1. Lo EH, Moskowitz MA, Jacobs TP. Exciting, radical, suicidal how brain cells die after stroke. Stroke. 2005;36:189 -192.
2. Hallenbeck JM, Duitka AJ. Background review and current concepts of reperfusion injury. Arch Neurol. 1990;47:1245-1254.
3. Baron JC, von Kummer R, del Zoppo GJ. Treatment of acute ischemic stroke challenging the concept of a rigid and universal time window. Stroke. 1995;26:2219-2221.
4. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. 2007;38:967-973.
5. Moussa HK. Nonocclusion and spontaneous recanalization rates in acute ischemic stroke: a review of cerebral angiography studies. Arch Neurol. 2002;59:1870-1873.
6. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EFM. FAHA guidelines for the early management of adults with ischemic stroke. A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Stroke. 2007;38:1655-1711.
7. Hill MD, Buchan AM; Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ. 2005; 172:1307-1312.
8. Evenson KR, Rosamond WD, Morris DL. Prehospital and in-hospital delays in acute stroke care. Neuroepidemiology. 2001;20: 65-76.
9. Pittock SJ, Meldrum D, Hardiman O, Deane C, Dunne P, Hussey A, Gorman M, Moroney JT. Patient and hospital delays in acute ischaemic stroke in a Dublin teaching hospital. Ir Med. 2003;96:167-168, 170-171.
10. Lacy CR, Suh DC, Bueno M, Kostis JB. Delay in presentation and evaluation for acute stroke: Stroke Time Registry for Outcomes Knowledge and Epidemiology (S.T.R.O.K.E.). Stroke. 2001;32:63-69.
11. Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Shuaib A, Ashwood T, Wasiewski W, Alderfer V, Hardemark HG, Rodichok L; for the SAINT I and II Investigators. NXY-059 for the treatment of Acute Stroke: pooled Analysis of the SAINT I and II trials. Stroke. 2008;39: 1751-1758.
12. Guadagno JV, Donnan GA, Markus R, Gillardb JH, Baron J-C. Imaging the ischaemic penumbra. Curr Opin Neurol. 2004;17:61-67.
13. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener H-C, Grotta J, Lyden P, Shuaib A, Hardemark H-G, Wasiewski W; for the Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators NXY-059 for Acute Ischemic Stroke. N Engl J Med. 2006;354:588-600.
14. Shuaib A, Lees KR, Lyden P, Grotta JC, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski W, Emeribe U; for the SAINT II Trial Investigators NXY-059 for the Treatment of Acute Ischemic Stroke. N Engl J Med. 2007;357:562-571.
15. Grotta JC. Neuroprotection is unlikely to be effective in human using current trial design. Stroke. 2002;33:306-307.
16. Sacchetti ML, Falcou A, Fieschi C. Experimental basis for combined treatment in acute ischemic stroke. In: Castillo J, Davalos A, Toni D, eds. Management of Acute Ischemic Stroke. Barcelona, Spain: Springer Verlag; 1997:253-262.
17. Sacchetti ML, Toni D, Fiorelli M, Argentino C, Fieschi C. The concept of combination therapy in acute ischemic stroke. Neurology. 1997;49 (Suppl. 4):S70-S74.
18. Steiner T, Hacke W. Combination therapy with neuroprotectants and thrombolytics in acute ischemic stroke. Eur Neurol. 1998;401-408.
19. The European Ad Hoc Consensus Group. Neuroprotection as initial therapy in Acute Stroke. Third Report of an Ad Hoc Consensus Group Meeting. Cerebrovasc Dis. 1998;8:59-72.
20. Davis M, Barer D. Neuroprotection in acute ischemic stroke II: Clinical potential. Vascular Medicine. 1999;4:149 -163.
21. Grotta JC. Combination therapy stroke trial: recombinant tissue-type plasminogen activator with/without lubeluzole. Cerebrovasc Dis. 2001; 12:258-263.
22. Toni D, Sacchetti ML, Chamorro A. Acute stroke trials: the problems of local investigators? Eur Neurol. 2003;49:109-114.
23. Lyden PD, Shuaib A, Lees KR, Davalos A, Davis SM, Diener H-C, Grotta JC, Ashwood TJ, Hardemark H-G, Svensson HH, Rodichok L, Wasiewski WW, Ahlberg G; for the CHANT Trial Investigators. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT trial. Stroke. 2007;38:2262-2269.
24. Fisher M, Hanley DF, Howard G, Jauch EC, Warach W; for the STAIR Group. Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke. 2007;38:245-248.